Compare ACHV & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHV | FTH |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.5M | 835.7M |
| IPO Year | 2018 | 2021 |
| Metric | ACHV | FTH |
|---|---|---|
| Price | $6.80 | $18.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $14.15 | ★ $55.38 |
| AVG Volume (30 Days) | ★ 1.3M | 345.2K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $16.57 |
| 52 Week High | $8.64 | $42.14 |
| Indicator | ACHV | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 33.59 |
| Support Level | $5.96 | N/A |
| Resistance Level | $7.30 | $21.97 |
| Average True Range (ATR) | 0.38 | 2.11 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 43.93 | 22.99 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.